Synvisc-One (hylan G-F 20, from Genzyme), has been FDAapproved for the relief of pain associated with osteoarthritis (OA) of the kneein patients who have failed to respond adequately to conservativenon-pharmacologic therapy and simple analgesics.  Synvisc-One is given as asingle-injection viscosupplement that is administered through an intra-articularinjection. It is an alternative treatment regimen to Genzyme’s Synvisc (hylanG-F 20), a three-injection viscosupplement.

For more information call (800) 745-4447 or visitwww.synvisc.com.